Available to mentor
Gil Omenn is Harold T. Shapiro Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health at the University of Michigan, Ann Arbor, USA. He served as Executive Vice President for Medical Affairs and as Chief Executive Officer of the University of Michigan Health System from 1997 to 2002. He was Dean of the School of Public Health, and Professor of Medicine and Environmental Health, University of Washington, Seattle, 1982-1997. He is the leader of the global Human Proteome Project (HPP) of the Human Proteome Organization (HUPO). His current research is focused on proteogenomics of alternative splicing in cancers. Splice variants are a major source of protein diversity in multi-cellular organisms with multi-exonic genes. Splice isoforms are good candidates for more specific biomarkers and therapeutic targets. He is author of 548 publications. Omenn has visited China 12 times since 1976. He is an honorary faculty of Peking Union Medical College, affiliate faculty of the Institute for Systems Biology in Seattle, member of the U.S. National Academy of Medicine, past president of the American Association for the Advancement of Science, board member of the Weizmann Institute of Science in Israel, and a director of several biotech companies. He served as a White House Fellow at the U.S. Atomic Energy Commission and as associate director of the White House Office of Science & Technology Policy and Office of Management & Budget. He earned the B.A. from Princeton University, M.D. from Harvard Medical School, and PhD in genetics from University of Washington. He is a musician and tennis player.
-
Center MemberRogel Cancer Center
-
Center MemberCenter for Computational Medicine and Bioinformatics
-
Center MemberInstitute for Healthcare Policy and Innovation
Dr. Omenn's research focuses on proteo-genomics of cancers and proteomics informatics. He long chaired and remains active in the Human Proteome Organization (HUPO) global Human Proteome Project (www.thehpp.org). There are datasets for application of analytical tools, and there are research teams eager to engage in collaborative studies in the Chromosome-centric HPP and Biology and Disease-driven HPP initiatives. He is a co-founder of the Consortium for Clinical Characterization of Covid-19 using Electronic Health Records (4CE) organized by the i2b2tranSMART Foundation and Harvard colleagues. He has long-standing interests in mechanisms of genetic predispositions to risks from environmental and occupational exposures (eco-genetics) and science-based risk analyses.
-
Savage SR, Wang Y, Chen L, Jewell S, Newton C, Dou Y, Li QK, Bathe OF, Robles AI, Omenn GS, Thiagarajan M, Zhang H, Hostetter G, Zhang B. Clin Proteomics, 2024 Jan 30; 21 (1): 7Journal ArticleFrozen tissue coring and layered histological analysis improves cell type-specific proteogenomic characterization of pancreatic adenocarcinoma.
DOI:10.1186/s12014-024-09450-3 PMID: 38291365 -
Sun D, Macedonia C, Chen Z, Chandrasekaran S, Najarian K, Zhou S, Cernak T, Ellingrod VL, Jagadish HV, Marini B, Pai M, Violi A, Rech JC, Wang S, Li Y, Athey B, Omenn GS. J Med Chem, 2024 Sep 26; 67 (18): 16035 - 16055.Journal ArticleCan Machine Learning Overcome the 95% Failure Rate and Reality that Only 30% of Approved Cancer Drugs Meaningfully Extend Patient Survival?
DOI:10.1021/acs.jmedchem.4c01684 PMID: 39253942 -
Li GX, Chen L, Hsiao Y, Mannan R, Zhang Y, Luo J, Petralia F, Cho H, Hosseini N, Leprevost FDV, Calinawan A, Li Y, Anand S, Dagar A, Geffen Y, Kumar-Sinha C, Chugh S, Le A, Ponce S, Guo S, Zhang C, Schnaubelt M, Al Deen NN, Chen F, Caravan W, Houston A, Hopkins A, Newton CJ, Wang X, Polasky DA, Haynes S, Yu F, Jing X, Chen S, Robles AI, Mesri M, Thiagarajan M, An E, Getz GA, Linehan WM, Hostetter G, Jewell SD, Chan DW, Wang P, Omenn GS, Mehra R, Ricketts CJ, Ding L, Chinnaiyan AM, Cieslik MP, Dhanasekaran SM, Zhang H, Nesvizhskii AI, Clinical Proteomic Tumor Analysis Consortium . Cell Rep Med, 2024 May 21; 5 (5): 101547Journal ArticleComprehensive proteogenomic characterization of rare kidney tumors.
DOI:10.1016/j.xcrm.2024.101547 PMID: 38703764 -
Hutch MR, Son J, Le TT, Hong C, Wang X, Shakeri Hossein Abad Z, Morris M, Gutiérrez-Sacristán A, Klann JG, Spiridou A, Batugo A, Bellazzi R, Benoit V, Bonzel C-L, Bryant WA, Chiudinelli L, Cho K, Das P, González González T, Hanauer DA, Henderson DW, Ho Y-L, Loh NHW, Makoudjou A, Makwana S, Malovini A, Moal B, Mowery DL, Neuraz A, Samayamuthu MJ, Sanz Vidorreta FJ, Schriver ER, Schubert P, Talbert J, Tan ALM, Tan BWL, Tan BWQ, Tibollo V, Tippman P, Verdy G, Yuan W, Avillach P, Gehlenborg N, Omenn GS, Consortium for Clinical Characterization of COVID-19 by EHR (4CE) , Visweswaran S, Cai T, Luo Y, Xia Z. PLOS Digit Health, 2024 Apr; 3 (4): e0000484Journal ArticleNeurological diagnoses in hospitalized COVID-19 patients associated with adverse outcomes: A multinational cohort study.
DOI:10.1371/journal.pdig.0000484 PMID: 38620037 -
Chu A, Hsiao Y, Deng Y, Wang C, Kyle J, Dou Y, Pino JC, Posso C, Henry L, Chen L, Li GX, Lih T-SM, Geffen Y, Yu F, Ding L, Omenn G, Kumar C, Dhanasekaran SM, Traer E, Tyner JW, Zhang H, Liu T, Gosline S, Zhang B, Chinnaiyan A, Nesvizhskii AI, Cieslik M. Cancer Research, 2024 Mar 22; 84 (6_Supplement): 7354 - 7354.Proceeding / Abstract / PosterAbstract 7354: Proteogenomic and metabolomic characterization of acute myeloid leukemia
DOI:10.1158/1538-7445.am2024-7354 -
Goldberg CB, Adams L, Blumenthal D, Brennan PF, Brown N, Butte AJ, Cheatham M, deBronkart D, Dixon J, Drazen J, Evans BJ, Hoffman SM, Holmes C, Lee P, Manrai AK, Omenn GS, Perlin JB, Ramoni R, Sapiro G, Sarkar R, Sood H, Vayena E, Kohane IS, RAISE Consortium . Nat Med, 2024 Mar; 30 (3): 623 - 627.Journal ArticleTo do no harm - and the most good - with AI in health care.
DOI:10.1038/s41591-024-02853-7 PMID: 38388841 -
Petralia F, Ma W, Yaron TM, Caruso FP, Tignor N, Wang JM, Charytonowicz D, Johnson JL, Huntsman EM, Marino GB, Calinawan A, Evangelista JE, Selvan ME, Chowdhury S, Rykunov D, Krek A, Song X, Turhan B, Christianson KE, Lewis DA, Deng EZ, Clarke DJB, Whiteaker JR, Kennedy JJ, Zhao L, Segura RL, Batra H, Raso MG, Parra ER, Soundararajan R, Tang X, Li Y, Yi X, Satpathy S, Wang Y, Wiznerowicz M, González-Robles TJ, Iavarone A, Gosline SJC, Reva B, Robles AI, Nesvizhskii AI, Mani DR, Gillette MA, Klein RJ, Cieslik M, Zhang B, Paulovich AG, Sebra R, Gümüş ZH, Hostetter G, Fenyö D, Omenn GS, Cantley LC, Ma'ayan A, Lazar AJ, Ceccarelli M, Wang P, Clinical Proteomic Tumor Analysis Consortium . Cell, 2024 Feb 29; 187 (5): 1255 - 1277.e27.Journal ArticlePan-cancer proteogenomics characterization of tumor immunity.
DOI:10.1016/j.cell.2024.01.027 PMID: 38359819 -
Goldberg CB, Adams L, Blumenthal D, Brennan PF, Brown N, Butte AJ, Cheatham M, deBronkart D, Dixon J, Drazen J, Evans BJ, Hoffman SM, Holmes C, Lee P, Manrai AK, Omenn GS, Perlin JB, Ramoni R, Sapiro G, Sarkar R, Sood H, Vayena E, Kohane IS. NEJM AI, 2024 Feb 22; 1 (3):Journal ArticleTo Do No Harm — and the Most Good — with AI in Health Care
DOI:10.1056/aip2400036